94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
Andreas Heinzel1†
Eva Schrezenmeier2†
Florina Regele1
Karin Hu1
Lukas Raab1
Michael Eder1
Christof Aigner1
Rhea Jabbour1
Constantin Aschauer1
Ana-Luisa Stefanski3
Thomas Dörner3
Klemens Budde2
Roman Reindl-Schwaighofer1*
Rainer Oberbauer1- 1Division of Nephrology and Dialysis, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria
- 2Department of Nephrology and Medical Intensive Care, Charité-Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
- 3Department of Rheumatology and Clinical Immunology, Charité-Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
by Heinzel, A., Schrezenmeier, E., Regele, F., Hu, K., Raab, L., Eder, M., Aigner, C., Jabbour, R., Aschauer, C., Stefanski, A.-L., Dörner, T., Budde, K., Reindl-Schwaighofer, R., and Oberbauer, R. (2022). Front. Med. 9:936126. doi: 10.3389/fmed.2022.936126
In the published article, an author name was incorrectly written as “Schretzenmeier.”
The correct spelling is “Schrezenmeier.”
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: COVID-19, kidney transplantation, COVID-19 vaccination, heterologous vaccination, third vaccination
Citation: Heinzel A, Schrezenmeier E, Regele F, Hu K, Raab L, Eder M, Aigner C, Jabbour R, Aschauer C, Stefanski A-L, Dörner T, Budde K, Reindl-Schwaighofer R and Oberbauer R (2022) Corrigendum: Three-Month follow-up of heterologous vs. homologous third SARS-CoV-2 vaccination in kidney transplant recipients: Secondary analysis of a randomized controlled trial. Front. Med. 9:1048395. doi: 10.3389/fmed.2022.1048395
Received: 19 September 2022; Accepted: 20 September 2022;
Published: 10 October 2022.
Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland
Copyright © 2022 Heinzel, Schrezenmeier, Regele, Hu, Raab, Eder, Aigner, Jabbour, Aschauer, Stefanski, Dörner, Budde, Reindl-Schwaighofer and Oberbauer. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Roman Reindl-Schwaighofer, cm9tYW4ucmVpbmRsLXNjaHdhaWdob2ZlckBtZWR1bml3aWVuLmFjLmF0
†These authors share first authorship